↓ Skip to main content

Anti-D administration after childbirth for preventing Rhesus alloimmunisation

Overview of attention for article published in Cochrane database of systematic reviews, April 1997
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Readers on

mendeley
52 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-D administration after childbirth for preventing Rhesus alloimmunisation
Published in
Cochrane database of systematic reviews, April 1997
DOI 10.1002/14651858.cd000021
Pubmed ID
Authors

Caroline A Crowther, Philippa Middleton

Abstract

The development of Rh immunisation and its prophylactic use since the 1970s has meant that severe Rhesus D (RhD) alloimmunisation is now rarely seen. The objective of this systematic review was to assess the effects of giving anti-D to Rhesus negative women, with no anti-D antibodies, who had given birth to a Rhesus positive infant. We searched the Cochrane Pregnancy and Childbirth Group trials register, the Cochrane Controlled Trials Register, MEDLINE (from 1966 to January 1999) and reference lists of relevant articles. Date of last search of Cochrane Controlled Trials Register: January 1999. Randomised trials in Rhesus negative women without antibodies who were given anti-D immunoglobulin postpartum compared with no treatment or placebo. Assessments of inclusion criteria, trial quality and data extraction were done by each author independently. Initial analyses included all trials. Other analyses assessed the effect of trial quality, ABO compatibility and dose. Six eligible trials compared postpartum anti-D prophylaxis with no treatment or placebo. The trials involved over 10,000 women, but trial quality varied. Anti-D lowered the incidence of RhD alloimmunisation six months after birth (relative risk 0.04, 95% confidence interval 0.02 to 0.06), and in a subsequent pregnancy (relative risk 0.12, 95% confidence interval 0. 07 to 0.23). These benefits were seen regardless of the ABO status of the mother and baby and when anti-D was given within 72 hours of birth. Higher doses (up to 200 micro grams) were more effective than lower doses (up to 50 micro grams) in preventing RhD alloimmunisation in a subsequent pregnancy. Anti-D, given within 72 hours after childbirth, reduces the risk of RhD alloimmunisation in Rhesus negative women who have given birth to a Rhesus positive infant. However the evidence on the optimal dose is limited.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Ireland 1 2%
Unknown 50 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 23%
Researcher 8 15%
Student > Master 7 13%
Other 6 12%
Student > Postgraduate 3 6%
Other 11 21%
Unknown 5 10%
Readers by discipline Count As %
Medicine and Dentistry 16 31%
Agricultural and Biological Sciences 10 19%
Nursing and Health Professions 8 15%
Social Sciences 4 8%
Biochemistry, Genetics and Molecular Biology 2 4%
Other 5 10%
Unknown 7 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 July 2020.
All research outputs
#9,521,080
of 15,543,024 outputs
Outputs from Cochrane database of systematic reviews
#9,357
of 11,212 outputs
Outputs of similar age
#130,211
of 239,971 outputs
Outputs of similar age from Cochrane database of systematic reviews
#135
of 157 outputs
Altmetric has tracked 15,543,024 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,212 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,971 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 157 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.